Beam Therapeutics Inc.

Beam Therapeutics Inc.

BEAMNYSE / NASDAQHealthcareSmall cap

$20.90-$0.04 (-0.2%)

Last close · Data as of Nov 20, 2026

Market cap
$3.4B
P/E
-42.2x
EV / EBITDA
-9.0x
Revenue
$139.7M
Net margin
-57.2%
ROCE
-27.7%

+1.5% over the last year

Beam Therapeutics Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-16.2%
3M
-26.4%
6M
-22.9%
1Y
+1.5%
5Y
-76.7%

52-week range

Day change -$0.04 (-0.2%) from $21 to $21 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in BEAM, bought on each weekday since 2021.

News & filings

What Beam Therapeutics filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 80.0 million US dollars in fiscal 2025.

Strengths (1)

  • Revenue more than doubled in fiscal 2025.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.

Read moreShow less

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Sector
Healthcare
Shares outstanding
101.8M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$3.4B
P/E
-42.2x
P/B
2.7x
EV / EBITDA
-9.0x
EV / Sales
23.2x
P/S
24.2x
52-week high
$37.92
52-week low
$20.60

Profitability

Operating margin
-274.6%
Net margin
-57.2%
EBITDA margin
-258.6%
ROE
-6.5%
ROCE
-27.7%
ROIC
-27.6%
ROA
-5.4%
Asset turnover
0.09

Growth

Revenue
$139.7M
Revenue growth, 1Y
120.0%
Revenue CAGR, 3Y
31.9%
Net profit growth, 1Y
-78.8%
Free cash flow
-$360.0M

Solvency

Current ratio
13.09
Debt / Equity
0.12
Debt / Assets
0.10
CFO / Net profit
4.31
Cash / Market cap
8.7%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$139.7M
Gross profit$139.7M
Operating expenses$523.4M
Research and development$409.6M
Selling, general and administrative$113.8M
Operating income-$383.7M
Interest and other$303.7M
Pretax income-$80.0M
Tax and other$0.00
Net income-$80.0M

Revenue and net profit

Revenue grew 120.0% in FY2025; net profit is the dashed line.

Beam Therapeutics Inc. revenue and net profit by fiscal year
Beam Therapeutics Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$60.9M-$289.1M
FY2023$377.7M-$132.5M
FY2024$63.5M-$376.7M
FY2025$139.7M-$80.0M

Cash flows

FY2025: -$345.1M from operations, -$360.0M free after investment (dashed).

Beam Therapeutics Inc. operating and free cash flow by fiscal year
Beam Therapeutics Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$22.5M-$26.4M
FY2023-$149.2M-$182.9M
FY2024-$347.2M-$356.2M
FY2025-$345.1M-$360.0M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$139.7M+120.0%1Y
EBITDA
-$361.4M
Net profit
-$80.0M
Cash from operations
-$345.1M
Free cash flow
-$360.0M
Revenue CAGR, 3Y
31.9%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$139.7M-$361.4M-$80.0M-$360.0M-6.5%+120.0%-78.8%

Monthly returns

Month-by-month returns of BEAM across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$1.5B
Liabilities$242.8M
Equity$1.2B
Paid-in capital$2.9B
Retained earnings-$1.6B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; BEAM highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Beam Therapeutics Inc. (this company)23.2x

Not shown (no positive earnings and no EV / Sales): Denali Therapeutics Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Beam Therapeutics Inc.BEAMthis company$3.4B-42.2x2.7x-6.5%-9.0x
Crinetics Pharmaceuticals, Inc.CRNX$3.7B-7.8x3.7x-46.9%-7.0x
iRhythm Holdings, Inc.IRTC$3.5B-79.2x23.1x-29.2%-1014.6x
Tango Therapeutics, Inc.TNGX$3.2B-31.5x9.3x-29.3%-28.7x
Denali Therapeutics Inc.DNLI$3.2B-6.2x3.2x-50.6%-5.6x
Haemonetics CorporationHAE$3.2B32.6x4.0x12.2%15.5x
Relay Therapeutics, Inc.RLAY$3.2B-11.5x5.6x-48.8%-10.4x
Option Care Health, Inc.OPCH$3.2B15.2x2.4x15.6%10.3x
Alignment Healthcare, Inc.ALHC$3.1B—17.4x-0.4%62.7x
Peer median—-7.8x4.8x-29.3%-6.3x

Year-to-date ROI

BEAM since 1 January, against earlier years.

Historical volatility

BEAM's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Beam Therapeutics Inc. operating margin by fiscal year
Beam Therapeutics Inc. operating margin by fiscal year
DateOperating margin
FY2022-555.6%
FY2023-46.7%
FY2024-654.2%
FY2025-274.6%
LineFY2025
Operating expensesOperating Expense$523.4M
Research and developmentResearch And Development$409.6M
Total expensesTotal Expenses$523.4M
Pretax incomePretax Income-$80.0M

Learn while you research

Academy chapters picked for Beam Therapeutics Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing120% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →